Clinical Trial Update: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate the safety and tolerability of ASP7317 in senior adults with geographic atrophy secondary to dry age-related macular degeneration; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• ASP7317

Snippet

Sponsor: Astellas Institute for Regenerative Medicine | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: RECRUITING